ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)
study id #: NCT04561518
condition: Transthyretin-Mediated Amyloidosis, ATTR Amyloidosis
status: Recruiting
purpose:The purpose of this study is to:
Describe epidemiological and clinical characteristics, natural history and real-world clinical management of ATTR amyloidosis patients
Characterize the safety and effectiveness of patisiran as part of routine clinical practice in the real-world clinical setting
Describe disease emergence/progression in pre-symptomatic carriers of a known disease-causing transthyretin (TTR) mutation
results: https://clinicaltrials.gov/ct2/show/results/NCT04561518
last updated: March 10, 2024
-
New and Evolving Concepts Regarding the Prognosis and Treatment of Cardiac AmyloidosisSystemic amyloidoses are rare and protei...
-
Eli Muchtar, MDEli Muchtar is a hematologist at Mayo cl...
-
Amyloidosis: Latest ResearchDoctors are working to learn more about ...
-
Cerebral Amyloid Angiopathy Research CenterCerebral Amyloid Angiopathy Research Cen...
-
Intellia CRISPR CAS9 Update – ASG Webinar 11/11https://www.youtube.com/watch?v=K2TmwAfu...
-
Panel Comments on Pharmaceutical Trials – ASG Webinar 1.25.24 – 9/9https://www.youtube.com/watch?v=A9g6r1PQ...
-
Tips for Living Your Best Life With hATTR AmyloidosisAfter being diagnosed with hATTR amyloid...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.